Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist investor Starboard Value has invested approximately $1 billion in Pfizer ...

Skyrizi had an estimated national TV ad spend of $93.7 million — the highest amount of any brand in the top 10 during this ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that Arexvy has been approved in Malaysia for respiratory ...

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV ...

These include the demand and stocking levels for US Arexvy, trends for Shingrix in the US market, and the development of the company's partnership in China. Additionally, the potential impact of ...

The revision comes as the analyst anticipates GlaxoSmithKline's third-quarter sales and profits to likely fall short of consensus estimates, primarily due to weaker than expected performance of US ...

RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...

First discovered in chimpanzees in 1956 and in children the following year, respiratory syncytial virus (RSV) isn’t new.

AI (in this case, ChatGPT) is an amazing tool for science and medical writers. But it's not perfect. It sometimes makes ...